Terminated × Interventional × peginterferon alfa-2b × Clear all Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Phase 1 Terminated
18 enrolled 19 charts
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
Phase 2 Terminated
12 enrolled 8 charts
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
Phase 2 Terminated
4 enrolled 9 charts
SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)
Phase 2/3 Terminated
126 enrolled 9 charts
Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL
Phase NA Terminated
7 enrolled 5 charts
Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion
Phase 1 Terminated
17 enrolled
PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron
Phase 2 Terminated
1 enrolled
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
Phase 2 Terminated
5 enrolled 3 charts
PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
Phase 2 Terminated
10 enrolled 4 charts
Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma
Phase 4 Terminated
13 enrolled 15 charts
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
Phase 1/2 Terminated
10 enrolled
PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
Phase 1 Terminated
1 enrolled 2 charts
Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase 1 Terminated
30 enrolled
PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
Phase 1/2 Terminated
30 enrolled